Cannabidiol as a candidate pharmacotherapy for sleep disturbance in alcohol use disorder

Among individuals with alcohol use disorder (AUD), it is estimated that the majority suffer from persistent sleep disturbances for which few candidate medications are available. Our aim wass to critically review the potential for cannabidiol (CBD) as a treatment for AUD-induced sleep disturbance. As context, notable side effects and abuse liability for existing medications for AUD-induced sleep disturbance reduce their clinical utility. CBD modulation of the endocannabinoid system and favorable safety profile have generated substantial interest in its potential therapeutic use for various medical conditions. A number of preclinical and clinical studies suggest promise for CBD in restoring the normal sleep-wake cycle and in enhancing sleep quality in patients diagnosed with AUD. Based on its pharmacology and the existing literature, albeit primarily preclinical and indirect, CBD is a credible candidate to address alcohol-induced sleep disturbance. Well-designed RCTs will be necessary to test its potential in managing this challenging feature of AUD.

Automated summary

Considering the limited availability of candidate medications for sleep disturbances in individuals with alcohol use disorder (AUD), this review critically examines the potential of cannabidiol (CBD) as a treatment for AUD-induced sleep disturbance. CBD's modulation of the endocannabinoid system and its favorable safety profile have generated substantial interest for its therapeutic use. Preclinical and clinical studies suggest promise for CBD in restoring normal sleep-wake cycle and enhancing sleep quality in AUD patients. Well-designed randomized controlled trials are needed to further investigate CBD's potential in managing this challenging feature of AUD.